一 | Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。
二 | 送医检查后发现，孩子上唇伤口需要缝合，一颗门牙被踢掉，另一颗松动脱落，而因牙床受损，随后又有两颗乳牙在治疗中相继脱落。
三 | 襄阳科技馆在采访中表示，机器人的操作人员当时没有判断好安全距离，导致事故发生。“我们家孩子这半年多来以吃流食为主，牙龈还经常发炎导致高烧，吃了很多苦。而由于面部留下疤痕，她的心理也遭受不小的打击。”女童母亲王女士告诉记者。扬子晚报记者了解到，事发至今已经9个多月过去了，目前女孩家长和涉事几方仍未就赔偿金额达成协议。提供机器人表演的合肥安达创展科技股份有限公司、襄阳市科技馆以及幼儿园对责任和赔偿态度各不相同。
四 | 王女士介绍，机器人公司目前提出除了医疗费外，愿意另外支付2万元进行调解，但孩子后续恢复祛疤费用高昂，几年后还要进行二次手术，家属希望一次性获赔15万元。这涵盖已经发生的医疗、交通等费用和今后的疤痕、牙齿治疗等费用。记者了解到，几方的分歧主要在于对尚未发生的美容修复等项目费用上，安达创展公司建议家长走法律诉讼途径解决。
Current article:http://rvl.niaozaogunbaizhaiguaweng.bond/1e76/20260826/63651.html
Published on:00:00:00
